Redeye returns with an updated assessment of Idogen following the advancement of its lead project IDO 8 and the forthcoming start of its clinical phase l/lla trial. We emphasize that the share price stands in contrast to this, currently trading at a single-digit enterprise value, offering an upside opportunity.